Apellis Reports Positive Interim Results from Phase 1b Clinical Trials of APL-2 in PNH
December 02, 2016 08:00 ET
|
Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present...
Apellis to Present Safety and Efficacy Data from Clinical Trials of APL-2 in PNH at December Scientific Meetings
November 21, 2016 08:00 ET
|
Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, announced today it will...
Akari Therapeutics to Attend Upcoming Investor Conferences In November
November 11, 2016 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...
Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology
November 03, 2016 09:01 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the...
Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs
November 03, 2016 09:00 ET
|
Achillion Pharmaceuticals, Inc.
Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016Achillion’s phase I MAD study with oral factor D inhibitor...
Akari Therapeutics to Present Abstract on Potential Once Weekly PAS-Coversin at the 58th Annual Meeting of the American Society of Hematology
November 03, 2016 08:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that an abstract has been...
Akari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York City
September 16, 2016 12:18 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Sept. 16, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced that Dr. Gur Roshwalb, Chief...
Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
September 12, 2016 07:15 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and...
Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
September 06, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into...
Achillion to Present at Two Upcoming Investor Conferences
September 01, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...